Contributor Page
Smart & Biggar/Fetherstonhaugh
 
Email  |  Website  |  Articles
Contact Details
Tel: +1 416 5935514
Fax: +1 416 5911690
1100-150 York Street
Toronto
ON M5H 3S5
Canada
By Smart & Biggar/Fetherstonhaugh
For complete details about these proceedings, click here.
By Abigail Smith
As previously reported, in December 2017, Apotex was awarded over $11M in damages and pre-judgment interest for losses flowing from delays ...
By Lynn Ing
The Federal Court has dismissed Elanco's application for judicial review of the Minister of Health's refusal to list Canadian Patent No. 2,812,704 on the Patent Register ...
By Andrew Mandlsohn
As previously reported, the Federal Court of Appeal (FCA) allowed in part Apotex's appeal of a decision awarding Eli Lilly over $100 million for Apotex's infringement ...
By Katie Lee
The SAC-HPW will provide advice on issues regarding women's health and regulation of medical devices and drugs.
By Urszula Wojtyra
As previously reported, Health Canada conducted stakeholder consultations and analysis of issues related to the naming of biologic drugs, including biosimilars.
By Alice Tseng, Eleanor Wilson
The Rebate Order at issue states for means that the benefit is linked directly or indirectly to listed or interchangeable products sold or offered for sale to the pharmacy.
By Brandon Heard
As previously reported, the Federal Court, in a pair of decisions, granted orders prohibiting Apotex and Teva from marketing their generic o-desmethyl-venlafaxine succinate products until expiry of Patent No. 2,436,668.
By Alice Tseng, Chen Li (Articling Student)
The OHIP+ program, also known as Children and Youth Pharmacare program, was implemented on January 1, 2018 by the Province of Ontario to provide free prescription drug coverage for all children and youth 24 years...
By Philip Lapin
As recently reported, Canadian trademark law will be overhauled on June 17, 2019 with many significant changes, both procedural and substantive, coming into effect.
By Urszula Wojtyra
On the eve of a section 8 trial, the Ontario Superior Court granted Abbott and Takeda leave to amend their pleadings to assert that Apotex's purported non-infringing alternative (NIA)
By Smart & Biggar/Fetherstonhaugh
For complete details about these proceedings, click here.
By Brandon Heard
As previously reported, the Ontario Court of Appeal (ONCA) granted Sanofi and Schering leave to amend their defences to plead the Supreme Court of Canada's decision ...
By Tierney Deluzio
The Generic Submissions Under Review (GSUR) list (previously reported) is a list of Abbreviated New Drug Submissions (generic submissions) ...
By Katie Lee
On December 20, 2018, Health Canada published an Action Plan on Medical Devices: Continuously Improving Safety, Effectiveness and Quality.